🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseFibrosis regression on GLP-1 — is scarring really reversible?

Fibrosis regression on GLP-1 — is scarring really reversible?

Dr.PathRoch Sat, May 30, 2026 at 3:14 PM 21 replies 557 viewsPage 1 of 5
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
May 30, 2026 at 3:14 PM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

What I am after is whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is. Practical detail welcome, however dull — the duller the better.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
13 8MikeFit_NJ, InsuranceTom, WendyG_ATL and 10 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
May 30, 2026 at 3:16 PM#2
Dr.PathRoch said:
The liver data is among the strongest non-weight findings in the class.

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
12 7VanRx_Mike, steve_okc, dave_SLC and 9 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
May 30, 2026 at 3:18 PM#3
Dr.PathRoch said:
The liver data is among the strongest non-weight findings in the class.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

Last edited: May 30, 2026 at 6:18 PM
11 6Dr.SleepRoch, laura_annarbor, JenMemphis and 8 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
May 30, 2026 at 3:20 PM#4
LabKate said:
Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Liver enzyme update related to liver and MASH: I had mildly elevated ALT/AST at baseline (likely NAFLD). After 8 months on GLP-1 therapy:

MarkerBaselineCurrentNormal Range
ALT73307-56 U/L
AST562410-40 U/L
GGT73369-48 U/L
ALP1038044-147 U/L

FibroScan also improved — liver stiffness from 10.5 kPa to 5.2 kPa. The evidence for GLP-1 agonists in NAFLD/NASH is very promising.

10 5LindaRN_retired, tommy_boulder, hyun_seoul and 7 others
Reply Quote Save Share Report
matt_MKE
Member
312
1,345
Sep 2024
Milwaukee, WI
May 30, 2026 at 3:30 PM#5
kate.chem said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Same experience, arrived at from the opposite direction. I had assumed I was the exception until I read this.

9 4DanielChem_CHI, marco_milano, pam_columbus and 6 others
Reply Quote Save Share Report
1235

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register